Supportive care in hematologic malignancies, including hematopoietic growth factors, transfusions, and infectious complications

Current Opinion in Hematology

Volumn 4, Issue 4, 1997, Pages 248-255

  Fetscher, Sebastian ^a   Mertelsmann, Roland ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR;

HUMAN; INFECTIOUS COMPLICATION; LEUKEMIA; LYMPHOMA; MYELOMA; PRIORITY JOURNAL; REVIEW; TRANSFUSION;

EID: 0030813314     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199704040-00005     Document Type: Review

References (65)

1. American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol 1994, 12:2471-2508. Authoritative summary of the published evidence for the safe and economical use of colony-stimulating factors in hematology and oncology.
2. Update of American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol 1996, 14:1957-1960. Update of the 1994 recommendations; mandatory referral for clinical, economical, and ethical assessment of routine and experimental use of colony-stimulating factors.
3. Spyridonidis A, Mertelsmann R, Henschler R: Hematopoietic cell proliferation and differentiation. Curr Opin Hematol 1996, 3:321-328.
4. Kaushansky K: Thrombopoietin and platelet development. West J Med 1996, 164:209-211.
5. Weite K, Reiter A, Mempel K, Pfetsch M, Schwab G, Schrappe M, Riehm H: A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia: Berlin-Frankfurt-Münster Study Group. Blood 1996, 87:3143-3150. Important study documenting the ability of G-CSF to reduce neutropenia and infectious complicatins in acute lymphoblastic leukemia, therefore improving adherence to the tight time frame of curative acute lymphoblastic leukemia chemotherapy protocols.
6. Baer MR, Bernstein SH, Brunetto VL, Heinonen K, Mrozek K, Swann VL, Minderman H, Block AW, Pixley LA, Christiansen NP, et al.: Biological effects of recombinant human granulocyte colony-stimulating factor in patients with untreated acute myeloid leukemia. Blood 1996, 87:1484-1494.
7. Beguin Y, Lampertz S, Bron D, Fillet G: Serum erythropoietin levels in chronic lymphocytic leukaemia. Br J Haematol 1996, 93:154-156.
8. Corcione A, Corrias MV, Daniele S, Zupo S, Pistoia V: Expression of granulocyte colony-stimulating factor and granulocyte colony-stimulating factor receptor genes in partially overlapping monoclonal B-cell populations from chronic lymphocytic lymphoma patients. Blood 1996, 87:2681-2689.
9. Österborg A, Boogaerts MA, Cimino R, Essers U, Holowiecki J, Juliusson G, Jager G, Najman A, Peest D: Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma - a randomized multicenter study: the European Study Group of erythropoietin (epoetin beta) treatment in multiple myeloma and non-Hodgkin's lymphoma. Blood 1996, 87:2675-2682.
10. Younes A, Sarris A, Consili U, Rodriguez A, McLaughlin P, Huh Y, Starry S, Canbanillas F, Andreed M: A pilot study of high-dose interleukin-3 treatment of relapsed follicular small cleaved cell non-Hodgkin's lymphoma: hematologic, immunologic, and clinical results. Blood 1996, 87:1698-1703.
11. Geissler K, Peschel C, Niederwieser D, Strobl H, Goldschmitt J, Ohler L, Bettelheim P, Kahls P, Huber C, Lechner K, et al.: Potentiation of granulocyte colony-stimulating factor-induced mobilization of circulating progenitor cells by seven-day pretreatment with interleukin-3. Blood 1996, 87:2732-2739.
12. Caux C, Vanbervliet B, Massacrier C, Durand I, Banchereau J: Interleukin-3 cooperates with tumor necrosis factor alpha for the development of human dendritic/Langerhans cells from cord blood CD34+ hematopoietic progenitor cells. Blood 1996, 87:2376-2385.
13. Scopes J, Daly S, Atkinson R, Ball SE, Gordon-Smith EC, Gibson FM: Aplastic anemia: evidence for dysfunctional bone marrow progenitor cells and the corrective effect of granulocyte colony stimulating factor in vitro. Blood 1996, 87:3179-3185.
14. Cortes JE, Talpaz M, Kantarijan H: Chronic myelogenous leukemia: a review. Am J Med 1996, 100:555-570.
15. Doney K, Leisenring W, Storb R, Appelbaum FR: Primary treatment of acquired aplastic anemia with bone marrow transplantation and immunosuppressive therapy. Ann Intern Med 1997, 126:107-115.
16. Rackoff WR, Orazi A, Robinson CA Cooper RJ, Alter BP, Freedman MH, Harris RE, Williams DA: Prolonged administration of granulocyte colony-stimulating factor (filgrastim) to patients with Fanconi anemia: a pilot study. Blood 1996, 88:1588-1593.
17. Charles RJ, Sabo KM, Kidd PG, Abkowitz JL: The pathophysiology of pure red cell aplasia: implications for therapy. Blood 1996, 87:4831-4838.
18. Negrin RS, Stein R, Doherty K, Cornwell J, Vardiman J, Krantz S, Greenberg PL: Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood 1996, 87:4076-4081.
19. MacVittie TJ, Farese AM, Herodin F, Grab LB, Baum CM, McKearn JP: Combination therapy for radiation-induced bone marrow aplasia in nonhuman primates using synthokine SC55494 and recombinant human granulocyte colony-stimulating factor. Blood 1996, 87:4129-4135.
20. Farese AM, Herodin F, McKearn JP, Baum C, Burton E, MacVittie TJ: Acceleration of hematopoietic reconstitution with a synthetic cytokine (SC-55494) after radiation-induced bone marrow aplasia. Blood 1996, 87:581-591.
21. Mavroudis D, Read E, Cottler-Fox M, Couriel D, Molldrem J, Carter C, Yu M, Dunbar C, Barrett J: CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies. Blood 1996, 88:3223-3229.
22. Waller CF, Bertz H, Wenger MK, Fetscher S, Hardung M, Engelhardt M, Behringer D, Lange W, Mertelsmann R, Finke J: Mobilization of peripheral blood progenitor cells for allogeneic transplantation: efficacy and toxicity of a high-dose rh-GCSF regimen. Bone Marrow Transplant 1996, 18:279-283.
23. Korbling M, Champlin R: Peripheral blood progenitor cell transplantation: a replacement for marrow auto- or allografts. Stem Cells (Dayt) 1996, 14:185-195.
24. Frickhofen N, Korbling M, Fliedner TM: Is blood a better source of allogeneic hematopoietic stem cells for use after radiation accidents? Bone Marrow Transplant 1996, 17:131-135.
25. Dreger P, Glass B, Uharek L, Schmitz N: Allogeneic peripheral blood progenitor cells: current status and future directions. J Hematother 1996, 5:331-337
26. Dreger P, Suttorp M, Haferlach T, Loffler H, Schmitz N, Schroyens W: Allogeneic granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for treatment of engraftment failure after bone marrow transplantation. Blood 1993, 81:1404-1407.
27. Gazitt Y, Tian E, Barlogie B, Reading CL, Vesole DH, Jagannath S, Schnell J, Hoffman R, Tricot G: Differential mobilization of myeloma cells and normal hematopoietic stem cells in multiple myeloma after treatment with cyclophosphamide and granulocyte-macrophage colony-stimulating factor. Blood 1996, 87:805-811. This study highlights the extreme importance of a schedule-oriented screening of leukapheresis products for the presence of contaminating malignant cells in myeloma.
28. Pierelli L, Scambia G, Menichella G, d'Onofrio G, Salerno G, Panici PB, Foddai ML, Vittori M, Lai M, Ciarli M, et al.: The combination of erythropoietin and granulocyte colony-stimulating factor increases the rate of haemopoietic recovery with clinical benefit after peripheral blood progenitor cell transplantation. Br J Haematol 1996, 92:287-294.
29. deSauvage FJ, Mass PE, Spencer SD: Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mp1 ligand. Nature 1995, 369:533-538.
30. Young JC, Bruno E, Luens KM, Wu S, Backer M, Murray LJ: Thrombopoietin stimulates megakaryocytopoiesis, myelopoiesis, and expansion of CD34+ progenitor cells from single CD34+Thy1+Lin-primitive progenitor cells. Blood 1996, 88:1619-1631.
31. Oda A, Miyakawa Y, Druker BJ, Ozaki K, Yabusaki K, Shirasawa Y, Handa M, Kato T, Miyazaki H, Shimosaka A, Ikeda Y: Thrombopoietin primes human platelet aggregation induced by shear stress and by multiple agonists. Blood 1996, 87:4664-4670.
32. Komatsu N, Kunitama M, Yamada M, Hagiwara T, Kato T, Miyazaki H, Eguchi M, Yamamoto M, Miura Y: Establishment and characterization of the thrombopoietin-dependent megakaryocytic cell line, UT-7/TPO. Blood 1996, 87:4552-4560.
33. O'Malley CJ, Rasko JE, Basser RL, McGrath KM, Cebon J, Grigg AP, Hopkins W, Cohen B, O'Byrne J, Green MD, et al.: Administration of pegylated recombinant human megakaryocyte growth and development factor to humans stimulates the production of functional platelets that show no evidence of in vivo activation. Blood 1996, 88:3268-3298. Seminal study on thrombopoietin administration in humans with documentation of an efficacy and safety profile of this new and highly important HGF.
34. Grossmann A, Lenox J, Deisher TA, Ren HP, Humes JM, Kaushansky K, Sprugel KH: Synergistic effects of thrombopoietin and granulocyte colony-stimulating factor on neutrophil recovery in myelosuppressed mice. Blood 1996, 88:3363-3370.
35. Harker LA, Hunt P, Marzec UM, Kelly AB, Tomer A, Hanson SR, Stead RB: Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates. Blood 1996, 87:1833-1844.
36. Harker LA, Marzec UM, Hunt P, Kelly AB, Tomer A, Cheung E, Hanson SR, Stead RB: Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates. Blood 1996, 88:511-521.
37. Ku H, Yonemura Y, Kaushansky K, Ogawa M: Thrombopoietin, the ligand for the Mpl receptor, synergizes with steel factor and other early acting cytokines in supporting proliferation of primitive hematopoietic progenitors of mice. Blood 1996, 87:4544-4551.
38. Molineux G, Hartley CA, McElroy P, McCrea C, McNiece IK: Megakaryocyte growth and development factor stimulates enhanced platelet recovery in mice after bone marrow transplantation. Blood 1996, 88:1509-1514.
39. Ulich TR, del Castillo J, Senaldi G, Kinstler O, Yin S, Kaufman S, Tarpley J, Choi E, Kirley T, Hunt P, Sheridan WP: Systemic hematologic effects of PEG-rHuMGDF-induced megakaryocyte hyperplasia in mice. Blood 1996, 87:5006-5015.
40. Chang M, Suen Y, Meng G, Buzby JS, Bussel J, Shen V, van de Ven C, Cairo MS: Differential mechanisms in the regulation of endogenous levels of thrombopoietin and interleukin-11 during thrombocytopenia: insight into the regulation of platelet production. Blood 1996, 88:3354-3362.
41. Strauss G, Ballmaier M, Schulze H, Bogenberger J, Riehm H, Welte K: Significance of thrombopoietin and its receptor c-Mp in regulation of thrombocytopoiesis in thrombocytopenia. Klin Padiatr 1996, 208:168-171.
42. Emmons RV, Reid DM, Cohen RL, Meng G, Young NS, Dunbar CE, Shulman NR: Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood 1996, 87:4068-4071.
43. Oh H, Nakamura H, Yokota A, Asai T, Saito Y: Serum thrombopoietin levels in cyclic thrombocytopenia. Blood 1996, 87:4918.
44. Matsumura I, Kanakura Y, Kato T, Ikeda H, Horikawa Y, Ishikawa J, Kitayama H, Nishiura T, Tomiyama Y, Miyazaki H, Matsuzawa Y: The biologic properties of recombinant human thrombopoietin in the proliferation and megakaryocytic differentiation of acute myeloblastic leukemia cells. Blood 1996, 88:3074-3082.
45. Ohwada A, Rafii S, Moore MA, Crystal RG: In vivo adenovirus vector-mediated transfer of the human thrombopoietin cDNA maintains platelet levels during radiation- and chemotherapy-induced bone marrow suppression. Blood 1996, 88:778-764.
46. Kobayashi M, Laver JH, Kato T, Miyazaki H, Ogawa M: Thrombopoietin supports proliferation of human primitive hematopoietic cells in synergy with steel factor and/or interleukin-3. Blood 1996, 88:429-436.
47. Basser RL, Rasko JE, Clarke K, Cebon J, Green MD, Hussein S, Alt C, Menchaca D, Tomita D, Marty J, et al.: Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet 1996, 348:1279-1281. Important pioneering study clearly documenting the remarkable clinical efficacy and safety of thrombopoietin administration in cancer patients.
48. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ: The risk of transfusion-transmitted viral infections: the Retrovirus Epidemiology Donor Study. N Engl J Med 1996, 334:1685-1690.
49. Gratwohl A, Hermans J, Baldomero, for the European Group for Blood and Marrow Transplantation: Blood and marrow transplantation activity in Europe 1995. Bone Marrow Transplant 1997, 19:407-419.
50. Busch MP, Operskalski EA, Mosley JW, Lee TH, Henrard D, Herman S, Sachs DH, Harris M, Huang W, Stram DO: Factors influencing human immunodeficiency virus type 1 transmission by blood transfusion: Transfusion Safety Study Group. J Infect Dis 1996, 174:26-33.
51. Alfieri C, Tanner J, Carpentier L, Perpete C, Savoie A, Paradis K, Delage G, Joncas J: Epstein-Barr virus transmission from a blood donor to an organ transplant recipient with recovery of the same virus strain from the recipient's blood and oropharynx. Blood 1996, 87:812-817.
52. Manno CS: What's new in transfusion medicine? Pediatr Clin North Am 1996, 43:793-808.
53. Tretiak R, Laupacis A, Riviere M, McKerracher K, Souetre E: Cost of allogeneic and autologous blood transfusion in Canada: Canadian Cost of Transfusion Study Group. Can Med Assoc J 1996, 154:1501-1508.
54. Caillot D, Casasnovas O, Bernard A, Couaillier JF, Durand C, Cuisenier B, Solary E, Piard F, Petrella T, Bonnin A, et al.: Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997, 15:139-147.
55. Fetscher S, Potthoff K, Technau K, Waller CF, Finke J, Mertelsmann R, Lange W: Incidence and mortality of pulmonary aspergillosis after high-dose chemotherapy and autologous hematopoietic stem cell transplantation [abstract]. Blood 1996, 88(suppl 1):417.
56. Neilson JR, Harrison P, Skidmore SJ, King JA, Collingham KE, Milligan DW: Chronic hepatitis C in long term survivors of hematological malignancy treated in a single centre. J Clin Pathol 1996, 49:230-232.
57. Kelly DA: Hepatitis C infection after blood product transfusion. Arch Dis Child 1996 75:363-365.
58. Silvestri F, Pipan C, Barillari G, Zaja F, Fanin R, Infanti L, Russo D, Falasca E, Botta GA, Baccarani M: Prevalence of hepatitis C virus infection in patients with lymphoproliterative disorders. Blood 1996, 87:4296-4301.
59. Neilson J, Harrison P, Milligan DW, Skidmore SJ, Collingham KE: Hepatitis G virus in long-term survivors of haematological malignancy. Lancet 1996, 347:1632-1633.
60. Wang JT, Tsai FC, Lee CZ, Chen PJ, Sheu JC, Wang TH, Chen DS: A prospective study of transfusion-transmitted GB virus C infection: similar frequency but different clinical presentation compared with hepatitis C virus. Blood 1996, 88:1881-1886.
61. Alfieri C, Tanner J, Carpentier L, Perpete C, Savoie A, Paradis K, Delage G, Joncas J: Epstein-Barr virus (EBV) transmission from a blood donor to an organ transplant recipient with recovery of the same virus strain from the recipient's blood and oropharynx. Blood 1996, 87:812-817.
62. Landaw EM, Kanter M, Petz LD: Safety of filtered leukocyte-reduced blood products for prevention of transfusion-associated cytomegalovirus infection. Blood 1996, 87:4910.
63. Vaughan P: Creutzfeldt-Jakob disease latest unknown in struggle to restore faith in blood supply. Can Med Assoc J 1996, 155:565-568.
64. Dodelet V, Ricketts M, Cashman NR: Emerging problems in prion disease. Can Med Assoc J 1996, 155:549-551.
65. MacKnight C, Rockwood K: Bovine spongiform encephalopathy and Creutzfeldt-Jakob disease: implications for physicians. Can Med Assoc J 1996, 155:529-536.